Market Need

Self-administration of products, outside of the hospital setting, is increasing to reduce the burden on the healthcare system in chronic disease. However, most therapeutic products, particularly those in liquid form, require refrigeration during their use. The ability to store vaccines and therapeutic products outside the cold chain, at least for the duration of the in-use period, offers a clear benefit when the developing and commercialising products. In addition to extending the in-use stability, there is also a significant need for the distribution and storage of therapeutic drugs outside of the cold chain, often at higher temperatures, particularly within developing territories and when developing vaccines. However, achieving such thermostability is often very challenging using conventional formulation approaches.

What Arecor can do

Our Arestatâ„¢ technology has been proven to deliver significantly improved stability profiles across a broad range of proteins, peptides and vaccines (including adenovirus based vaccines) , providing enhanced thermostability leading to more convenient storage, delivery and easy-of-use for both the medical profession and patient alike.